Additionally, a clinical study demonstrated that low-dose UDCA intake enhances GLP-1 secretion through TGR5 signaling in patients with T2D [104], representing the first evidence in humans of increased GLP-1 levels and reduced blood glucose in response to UDCA. The gene discussed is GCG; the disease is type 2 diabetes mellitus.